An update from Fusion Antibodies Plc ( (GB:FAB) ) is now available.
Fusion Antibodies plc has announced the issuance of new ordinary shares to certain non-executive directors as part of their salary and fees for the six-month period ending March 31, 2025. This move is part of the company’s strategy to manage cash flows effectively, with a total of 338,113 shares issued at a price of 6.1p per share. The shares will be admitted to trading on AIM, increasing the total number of shares in issue to 113,656,253, which will impact the company’s voting rights structure.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc faces substantial financial hurdles with declining revenues and significant losses. Technical analysis indicates bearish momentum, and valuation metrics highlight unprofitability. Despite these challenges, recent corporate events, including successful fundraising and strategic collaborations, offer some optimism for future growth. However, the immediate financial health remains a primary concern, resulting in a low overall stock score.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. The company offers a wide range of services, including antibody generation, development, production, characterization, and optimization, and has a strong international client base, including major pharmaceutical companies.
Average Trading Volume: 835,352
Technical Sentiment Signal: Hold
Current Market Cap: £7.42M
For an in-depth examination of FAB stock, go to TipRanks’ Stock Analysis page.